Single-Dose heart drug tested for rare genetic condition
NCT ID NCT06534671
Summary
This study tested if a single intravenous dose of the drug diltiazem could safely shorten a dangerously long QT interval in adults with Jervell and Lange-Nielsen syndrome, a rare genetic disorder. The goal was to see if the drug could quickly reduce the heart's electrical instability. Only one adult participant was enrolled to have their heart rhythm closely monitored before and after receiving the medication.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for JERVELL AND LANGE NIELSEN SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States
Conditions
Explore the condition pages connected to this study.